Why the study?
Does the N291S mutation in the LPL gene alter the lipoprotein phenotype and increase the risk for cardiovascular disease in patients with familial hypercholesterolemia?
Does the N291S mutation in the LPL gene alter the lipoprotein phenotype and increase the risk for cardiovascular disease in patients with familial hypercholesterolemia?
The N291S mutation in the LPL gene significantly worsens the lipid profile and increases cardiovascular disease risk in patients with familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for N291S as CVD risk modifier in FH; requires prospective confirmation before clinical integration.
BACKGROUND: Recently, a mutation in the lipoprotein lipase (LPL) gene (N291S) has been reported in 2% to 5% of individuals in western populations and is associated with increased triglyceride (TG) and reduced HDL cholesterol (HDLC) concentrations. METHODS AND RESULTS: Here we report a significant alteration in biochemical and clinical phenotype in subjects with familial hypercholesterolemia (FH) who are heterozygous for this N291S LPL mutation. Sixty-four FH heterozygotes carrying the N291S mutation had significantly a higher TG level (P=.004), a higher ratio of total cholesterol to HDLC (P<.001), and lower HDLC concentrations (P=.002) compared with 175 FH heterozygotes without this LPL mutation. Moreover, the N291S mutation conferred a significantly greater risk for developing cardiovascular disease in FH heterozygotes compared with FH heterozygotes without this LPL mutation (odds ratio, 3.875; P=.006). CONCLUSIONS: These data provide evidence that a common LPL variant (N291S) significantly influences the biochemical phenotype and risk for cardiovascular disease in patients with FH.
No takes yet. Share an insight, caveat, or question.
Wittekoek et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: